February 2, 2001
Taisho to Release Lorcam Tablets:
Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) has announced that Lorcam tablets (generically, "lornoxicam"), an oxicam-derived nonsteroidal anti-inflammatory drug (NSAID) for the relief of pain, are scheduled for market release at the end of February 2001. Manufacturing approval was granted on December 22, 2000, but the announcement was delayed until a retail price could be finalized.
Slow absorption and slow metabolism in the body's system has been a conventional shortcoming with oxicam-derived NSAID products. Taisho overcame this with its quick-release technology. The proprietary technique enables active ingredients to be fully absorbed into the bloodstream in 30 to 40 minutes after ingestion (when taken on an empty stomach). Lorcam tablets are also fast acting. With increased metabolization and a shorter absorption half-life, Lorcam is also safe and effective for the elderly, as well as for patients with a history of digestive trouble.
Lornoxicam, first developed in 1977 by F. Hoffman-La Roche, Ltd., offered greater pain-relief and anti-inflammatory capabilities than had previously been available with such products. With faster absorption into the bloodstream from Taisho's quick-release know-how, Lorcam can deliver rapid pain relief for post-operative discomfort. Favorable metabolism rates also ensure that this product will remain effective in treating chronic pain in conditions such as chronic rheumatism.
In 1985, Chemie Linz (now Nycomed Pharma AS) began aggressively developing international markets for the product, which is now availableor has been approved for sale-in more than 20 countries around the world.
In Japan, Taisho in-licensed lornoxicam in 1988. Taisho acquired a patent for "quick-dissolving tablet medicines" in April 1999. By supplying Nycomed Pharma with the patented technology, Taisho anticipates significant global penetration for quick-release lornoxicam tablets.